Literature search results

5 articles were found.

The following terms were included: Carboplatin, カルボプラスチン

• 2024, Berckmans Y, Ene HM, Ben-Meir K, Martinez-Conde A, Wouters R, Van den Ende B, Van Mechelen S, Monin R, Frechtel-Gerzi R, Gabay H, Dor-On E, Haber A, Weinberg U, Vergote I, Giladi M, Coosemans A, Palti Y
  Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance [med./bio.]
  Front Oncol 14: 1402851
• 2019, Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, Mencoboni M, Planchard D, Chella A, Crinò L, Krzakowski M, Rüssel J, Maconi A, Gianoncelli L, Grosso F
  Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial [med. app.]
  Lancet Oncol 20 (12): 1702-1709
• 2018, Amiri M, Basiri M, Eskandary H, Akbarnejad Z, Esmaeeli M, Masoumi-Ardakani Y, Ahmadi-Zeidabadi M
  Cytotoxicity of carboplatin on human glioblastoma cells is reduced by the concomitant exposure to an extremely low-frequency electromagnetic field (50 Hz, 70 G) [med./bio.]
  Electromagn Biol Med 37 (3): 138-145
• 2001, Schreiber WG, Teichmann EM, Schiffer I, Hast J, Akbari W, Georgi H, Graf R, Hehn M, Spiebeta HW, Thelen M, Oesch F, Hengstler JG
  Lack of mutagenic and co-mutagenic effects of magnetic fields during magnetic resonance imaging [med./bio.]
  J Magn Reson Imaging 14 (6): 779-788
• 1994, Hannan Jr CJ, Liang Y, Allison JD, Searle JR
  In vitro cytotoxicity against human cancer cell lines during pulsed magnetic field exposure [med./bio.]
  Anticancer Res 14 (4A): 1517-1520